Agilent completes acquisition of Biovectra

Agilent Technologies announced the company has completed its acquisition of BIOVECTRA, a Canada-based contract development and manufacturing organization that specializes in biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics. All closing conditions are completed, including receipt of regulatory approvals. BIOVECTRA is now part of Agilent’s Diagnostics and Genomics Group. Agilent expects the transaction will be 5c dilutive to non-GAAP EPS in the first full year after closing and deliver a double-digit return on invested capital by year five. Agilent funded the transaction using a mix of cash on hand and debt financing.